Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=29468912
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Hormone treatments in congestive heart failure
#MMPMID29468912
Lei L
; Mao Y
J Int Med Res
2018[Jun]; 46
(6
): 2063-2081
PMID29468912
show ga
The common ultimate pathological feature for all cardiovascular diseases,
congestive heart failure (CHF), is now considered as one of the main public
health burdens that is associated with grave implications. Neurohormonal systems
play a critical role in cardiovascular homeostasis, pathophysiology, and
cardiovascular diseases. Hormone treatments such as the newly invented
dual-acting drug valsartan/sacubitril are promising candidates for CHF, in
addition to the conventional medications encompassing beta receptor blockers,
angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and
mineralocorticoid receptor antagonists. Clinical trials also indicate that in CHF
patients with low insulin-like growth factor-1 or low thyroid hormone levels,
supplemental treatment with growth hormone or thyroid hormone seems to be
cardioprotective; and in CHF patients with volume overload the vasopressin
antagonists can relieve the symptoms superior to loop diuretics. Furthermore, a
combination of selective glucocorticoid receptor agonist and mineralocorticoid
receptor antagonist may be used in patients with diuretic resistance. Finally,
the potential cardiovascular efficacy and safety of incretin-based therapies,
testosterone or estrogen supplementation needs to be prudently evaluated in
large-scale clinical studies. In this review, we briefly discuss the therapeutic
effects of several key hormones in CHF.
|Antidiuretic Hormone Receptor Antagonists/therapeutic use
[MESH]
free
free
free
